A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : VISA

Search Conditions:
Search Keyword : VISA
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: VISA
Appearance Frequency: 411 time(s)
Long forms: 34

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
vancomycin-intermediate S. aureus
(158 times)
Anti-Bacterial Agents
(70 times)
MRSA (87 times)
hVISA (47 times)
VRSA (35 times)
2000 In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
vancomycin-intermediate Staphylococcus aureus
(140 times)
Drug Therapy
(49 times)
MRSA (44 times)
hVISA (31 times)
VRSA (15 times)
1998 Highly virulent pathogens--a post antibiotic era?
vancomycin-intermediate resistant S. aureus
(31 times)
Medicine
(7 times)
MRSA (17 times)
VRSA (12 times)
MIC (5 times)
1998 [Methicillin-resistant Staphylococcus aureus (MRSA)--clinical implications].
Victorian Institute of Sport Assessment
(23 times)
Sports Medicine
(12 times)
VAS (5 times)
PRP (2 times)
PT (2 times)
1998 The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group.
virus-induced signaling adaptor
(19 times)
Allergy and Immunology
(8 times)
RIG-I (8 times)
IRF3 (6 times)
IFNs (5 times)
2007 VISA--a pass to innate immunity.
vancomycin-intermediate MRSA
(3 times)
Anti-Bacterial Agents
(3 times)
MRSA (3 times)
BLs (1 time)
DNS (1 time)
2006 Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002.
vision, inflammation, strabismus, and appearance
(3 times)
Eye Diseases
(2 times)
GO (3 times)
EUGOGO (1 time)
QLS (1 time)
2011 Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease.
VA-intermediate Staphylococcus aureus
(2 times)
Microbiology
(1 time)
BMD (1 time)
CFZ (1 time)
CWT (1 time)
2009 Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.
vancomycin susceptibility
(2 times)
Microbiology
(2 times)
BHI (1 time)
GRD (1 time)
MAC (1 time)
2011 Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
10  vancomycin-intermediate strains of S. aureus
(2 times)
Anti-Bacterial Agents
(1 time)
BHI-V3 (1 time)
CLSI (1 time)
MRSA (1 time)
2010 Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.
11  VCM-insensitive S. aureus
(2 times)
Drug Therapy
(2 times)
MRSA (2 times)
VCM (2 times)
Q-D (1 time)
2003 Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice.
12  Vision Impairment Screening Assessment
(2 times)
Medicine
(1 time)
--- 2018 Visual Impairment Screening Assessment (VISA) tool: pilot validation.
13  Vocational Identity Status Assessment
(2 times)
Pediatrics
(2 times)
--- 2011 A multi-dimensional measure of vocational identity status.
14  VP16-Gal4-WPRE integrated systemic amplifier
(2 times)
Antineoplastic Agents
(1 time)
CMV (1 time)
2009 A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
15  intermediate-vancomycin-resistant
(1 time)
Drug Therapy
(1 time)
CLSI (1 time)
MICs (1 time)
MRSA (1 time)
2007 Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan.
16  vancomycin insensitive S. aureus
(1 time)
Pharmacology
(1 time)
MRSA (1 time)
VRE (1 time)
2009 Discovery of medically significant lantibiotics.
17  vancomycin intermediate S. aureus strains were detected
(1 time)
Communicable Diseases
(1 time)
MICs (1 time)
MRSA (1 time)
MSSA (1 time)
2013 Methicillin resistant and susceptible Staphylococcus aureus: Appraising therapeutic approaches in the Northwest of Iran.
18  vancomycin intermediate-resistance
(1 time)
Communicable Diseases
(1 time)
MRSA (1 time)
PFGE (1 time)
2015 Vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolated from a patient who never received vancomycin treatment.
19  vancomycin resistance
(1 time)
Medicine
(1 time)
--- 2014 Intermediate-type vancomycin resistance (VISA) in genetically-distinct Staphylococcus aureus isolates is linked to specific, reversible metabolic alterations.
20  vancomycin-intermediate strains
(1 time)
Communicable Diseases
(1 time)
MRSA (1 time)
PRPN (1 time)
VRE (1 time)
2001 The oxazolidinones as a new family of antimicrobial agent.
21  vancomycin-intermediate susceptibility
(1 time)
Anti-Bacterial Agents
(1 time)
BMD (1 time)
MRSA (1 time)
PAP (1 time)
2011 Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
22  vancomycin-resistant S. aureus
(1 time)
Biology
(1 time)
CA-SFM (1 time)
hVISA (1 time)
MRSA (1 time)
2004 [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
23  vancomycin-resistant Staphylococcus aureus
(1 time)
Anti-Bacterial Agents
(1 time)
--- 2009 In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
24  vancomycin-resistant strain of S. aureus
(1 time)
Anti-Bacterial Agents
(1 time)
CT (1 time)
MRSA (1 time)
NJ (1 time)
2000 Distribution of methicillin-resistant Staphylococcus aureus clones among health care facilities in Connecticut, New Jersey, and Pennsylvania. .
25  Vascular lifestyle-Intervention and Screening in phArmacies
(1 time)
Nutritional Physiological Phenomena
(1 time)
CVD (1 time)
FFQ (1 time)
2018 Evaluation of a short Food Frequency Questionnaire to assess cardiovascular disease-related diet and lifestyle factors.
26  vector integration site analysis
(1 time)
Cell Biology
(1 time)
--- 2016 Genetic Tagging During Human Mesoderm Differentiation Reveals Tripotent Lateral Plate Mesodermal Progenitors.
27  Ventricular Ischemic Site Analysis
(1 time)
Cardiology
(1 time)
--- 1998 [A new computerized electrocardiographic method of the study of the QRS complex in the diagnosis of myocardial ischemia (preliminary results)].
28  viral insertion site amplification
(1 time)
Genetics
(1 time)
CISs (1 time)
RI (1 time)
VISION (1 time)
2007 Retroviral insertions in the VISION database identify molecular pathways in mouse lymphoid leukemia and lymphoma.
29  virus-induced surface antigen
(1 time)
Virology
(1 time)
CE (1 time)
HSCA (1 time)
1975 Evidence for a host cell surface antigen on the envelope of avian tumour viruses.
30  Visible to Infrared SASE Amplifier
(1 time)
Physics
(1 time)
FEL (1 time)
SASE (1 time)
2003 Properties of the ultrashort gain length, self-amplified spontaneous emission free-electron laser in the linear regime and saturation.
31  visual indicator for surfactant abundance
(1 time)
Chemistry Techniques, Analytical
(1 time)
LC (1 time)
MS (1 time)
2010 Visual indicator for surfactant abundance in MS-based membrane and general proteomics applications.
32  VIsual Sequence Analysis
(1 time)
Biology
(1 time)
--- 1994 VISA: Visual Sequence Analysis for the comparison of multiple amino acid sequences.
33  Visualization of Inter-Spike Associations
(1 time)
Neurology
(1 time)
--- 2010 iRaster: a novel information visualization tool to explore spatiotemporal patterns in multiple spike trains.
34  Voting for image scoring and assessment
(1 time)
Diagnostic Imaging
(1 time)
--- 2015 Voting for image scoring and assessment (VISA)--theory and application of a 2 + 1 reader algorithm to improve accuracy of imaging endpoints in clinical trials.